Sudeep Pharma Ltd

Sudeep Pharma Ltd announced the appointment of Mr. Milin Mehta as an Additional Director (Non-Executive Non-Independent) with immediate effect from June 26, 2026. The appointment is subject to shareholder approval. Mr. Mehta, a Chartered Accountant and Law Graduate, brings over three decades of experience in accounting, legal, and strategic expertise, currently serving as Managing Partner at K C Mehta & Co LLP. He has a strong background in tax litigation, international tax, and transfer pricing, and has contributed to national policy initiatives. He also serves on the boards of other listed and unlisted companies and is involved in educational and social causes. The company confirmed that Mr. Mehta has not been debarred from holding a director's office.

Sudeep Pharma Ltd announced the appointment of Mr. Milin Mehta as an Additional Director (Non-Executive & Non-Independent) effective June 26, 2026. The appointment was made during a Board of Directors meeting held on the same date. Mr. Mehta, a Chartered Accountant and Law Graduate with extensive experience in tax, transfer pricing, and transaction advisory services, brings a wealth of expertise to the board. He has held significant roles in professional bodies and contributed to policy initiatives. The company confirmed that Mr. Mehta has not been debarred from holding a director's office by any authority. His appointment is subject to shareholder approval.

Sudeep Pharma Limited has announced the closure of its trading window for designated persons and their immediate relatives, effective July 1, 2026. This closure is in anticipation of the adoption of the un-audited financial results for the quarter ending June 30, 2026. The trading window will remain shut until 48 hours after the declaration of these financial results. The company will inform stock exchanges about the board meeting date for approving these results in due course. This measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, to prevent insider trading.

Sudeep Pharma Ltd's Board of Directors, in a meeting held on May 21, 2026, recommended a final dividend of ₹1.50 (150%) per equity share of ₹1 each for the financial year ended March 31, 2026, subject to shareholder approval. The board also approved the appointment of M/s. Chetan Gandhi & Associates as the Cost Auditor for FY 2026-27 and M/s H M Mehta & Associates as the Secretarial Auditor for five years commencing from FY 2026-27 until 2030-31.

Sudeep Pharma Ltd's Board of Directors approved the audited standalone and consolidated financial results for the year ended March 31, 2026. They recommended a final dividend of ₹1.50 (150%) per equity share of ₹1 each, subject to shareholder approval. The board also approved the appointment of M/s. Chetan Gandhi & Associates as Cost Auditor for FY 2026-27 and M/s H M Mehta & Associates as Secretarial Auditor for five years from the conclusion of the 37th AGM until the 41st AGM.

Sudeep Pharma Ltd's board approved audited financial results for the year ended March 31, 2026, and recommended a final dividend of ₹1.50 per equity share (150%). They appointed M/s. Chetan Gandhi & Associates as Cost Auditor for FY 2026-27 and M/s H M Mehta & Associates as Secretarial Auditor for five years, commencing from FY 2026-27 until 2030-31, subject to shareholder approval at the upcoming AGM. The board meeting concluded on May 21, 2026.

Sudeep Pharma Ltd has scheduled a Board of Directors meeting on May 21, 2026, to consider and approve the audited standalone and consolidated financial results for the fourth quarter and year ended March 31, 2026. The board will also consider recommending a final dividend on equity shares for the financial year 2025-26. The trading window for insiders has been closed from April 1, 2026, and will remain closed until 48 hours after the declaration of the financial results, concluding on May 23, 2026.

Sudeep Pharma Ltd has announced the closure of the trading window for designated persons from 1st April 2026. The closure is in accordance with the Code of Conduct on Prevention of Insider Trading of Sudeep Pharma Limited and SEBI (Prohibition of Insider Trading) Regulations, 2015. The trading window will remain closed till 48 hours after the declaration of the Audited Standalone and Consolidated Financial Results for the year ending on March 31, 2026. This means that all Designated Persons and their immediate relatives are prohibited from dealing in the securities of the Company during this period. The date of the meeting of the Board of directors to approve the Audited Standalone & Consolidated Financial Results for the year ending on March 31, 2026, will be intimated separately.

Sudeep Pharma Ltd has appointed Sharp & Tannan Associate as the Internal Auditor for the financial year 2026-27. The appointment was made at the Board of Directors meeting held on 6th February 2026. The Board also considered and approved the Unaudited Standalone & Consolidated Financial Results for the third quarter and nine months ended on 31 December, 2025. Sharp & Tannan Associate is a well-established Chartered Accountancy firm with a focus on risk-based auditing and value-added approach to business processes. The firm has been proponents of the COSO 1992 framework and has started early adoption of RPAs/Robotics automations in the fields of internal audit and other consulting assignments.

Sudeep Pharma Ltd has appointed Sharp & Tannan Associate as the Internal Auditor for the financial year 2026-27. The appointment was made at the Board of Directors meeting held on 6th February 2026. The firm, established in 1934, is known for its risk-based auditing and value-added approach to business processes. Sudeep Pharma Ltd also released its unaudited standalone and consolidated financial results for the third quarter and nine months ended on 31st December 2025.